Everything Innovation. Everything New Jersey.
Follow us and stay connected.
Trenton, NJ - In another New Jersey first, Aprecia Pharmaceuticals company announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. 1 SPRITAM utilizes Aprecia's proprietary ZipDose® Technology platform, a groundbreaking advance that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid.
For the full article: https://www.aprecia.com/pdf/2015_08_03_Spritam_FDA_Approval_Press_Release.pdf
Do not miss a single innovative moment and sign up for our newsletter!